MedTrace Logo

Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma

NCT03687099 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-07-16

No results posted yet for this study

Summary

Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis. Immunotherapy by checkpoint inhibitors (PD1 /PDL-1) appears as a promising treatment for many cancers. However, first clinical results are disappointing for GBM. An hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. Conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.

Conditions

Interventions

OTHER

no intervention

Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2019-11-08
Completion
2019-11-08

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687099 on ClinicalTrials.gov